A higher percentage of patients with migraine who received ubrogepant — an experimental treatment — experienced freedom from their pain and the elimination of their most bothersome symptom 2 hours after they received the dose vs. patients who received placebo, according to results of a randomized trial published in The New England Journal of Medicine.
The drug, which is being developed by Allergan, is an oral, small-molecule calcitonin gene-related peptide receptor antagonist.
This activity is supported by an educational grant from Novo Nordisk Inc.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.